Metastatic carcinoma of the prostate: Identifying prognostic groups using recursive partitioning

Journal of Urology

Volumn 169, Issue 1, 2003, Pages 164-169

  Glass, Tracy R ^a,b,c   Tangen, Catherine M ^a,b,c   Crawford, E David ^a,b,c   Thompson, Ian ^a,b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Flutamide; Neoplasm metastasis; Orchiectomy; Prostate; Prostatic neoplasms

Indexed keywords

FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE PAIN; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

EID: 0037213862     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64059-1     Document Type: Article

References (13)

1. Jemal, A., Thomas, A., Murray, T. and Thun, M.: Cancer statistics, 2002. CA: Ca J Clin, 52: 23, 2002
2. Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J. et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med, 339: 1036, 1998
3. Breiman, L., Friedman, J. H., Olshen, R. A. and Stone, C. J.: Classification and Regression Trees. Belmont, California: Wadsworth Publishing Co., 1984
4. Crowley, J., LeBlanc, M., Jacobson, J. L. and Salmon, S. E.: Some exploratory tools for survival analysis. In: Proceedings of the First Seattle Symposium in Biostatistics: Survival Analysis. pp. 199-229, 1997
5. LeBlanc, M. and Crowley, J.: Survival trees by goodness of split. JASA, 88: 457, 1993
6. Cox, D. R.: Regression models and life-tables. J R Stat Soc Series B, 34: 187, 1972
7. Cox, D. R. and Snell, E. J. The Analysis of Binary Data, 2nd Ed. London: Chapman and Hall, 1989
8. Kaplan, E. L. and Meier, P.: Nonparametric estimation for incomplete observations. J Am Stat Assoc, 53: 457, 1958
9. Mantel, N.: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 50: 163, 1966
10. D'Amico, A. V., Schulz, D., Loffredo, M., Dugal, R., Hurwitz, M., Kaplan, I. et al: Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for localized prostate cancer. JAMA, 284: 1280, 2000
11. Kattan, M. W., Eastham, J. A., Stapleton, A. M. F., Wheeler, T. M. and Scardinoi, P. T.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst, 90: 766, 1998
12. D'Amico, A. V.: Combined-modality staging in predicting prostate-specific antigen outcome after definitive local therapy for men with clinically localized prostate cancer. In: Prostate Cancer: Principles and Practice. Philadelphia: Lippincott Williams and Wilkins Co., pp. 254-268, 2002
13. Brufsky, A., Fontaine-Rothe, P., Berlane, K., Rieker, P., Jiroutek, M., Kaplan, I. et al: Finasteride and flutamide as potency-sparing androgen ablative therapy for advanced adenocarcinoma of the prostate. Urology, 49: 913, 1997